The rise of China’s health care sector

Liqian Ren, Director of Modern Alpha

U.S. Department of Defense (2.86 million)

People’s Liberation Army of China (2.52 million)

Walmart (2.3 million)

McDonald’s (1.9 million)

U.K.’s National Health Service (1.7 million)

What do the five items in this list have in common? They are the world’s biggest employers. 

The list is interesting from another perspective. In China, aside from a small percentage who bravely jumped into the private health sector, most doctors and nurses are technically civil servants.

As of 2017, there were 3.39 million licensed doctors in China, up from 2.12 million in 2007. 

Superagency

A newly established superagency, the National Healthcare Security Administration (NHSA), has been charged to lead everything health-care-related in China.

If China starts imitating the health care model of U.K.’s National Health Service (NHS), the NHSA has the potential to become the world’s biggest employer.  

Health care is an important part of financial markets as well.

The sector makes up 15% of the S&P 500 Index as of the end of June, while the MSCI China Index is only 3% health care. 


China Power

On last week’s episode of “Behind the Markets,” we had two guests who are experts in both U.S. and Chinese health care policies.  

Dr. Zhou Yang, health policy advisor to the World Bank Group, obtained her Ph.D. in health economics from the University of North Carolina at Chapel Hill, and has also taught at Emory University and the University of Florida.  

Dr. Mark McClellan is a former administrator for the Centers for Medicare & Medicaid Services (CMS) and a former commissioner of the U.S. Food and Drug Administration (FDA).

He’s the Robert J. Margolis Professor of Business, Medicine, and Policy, and directs the Duke-Margolis Center for Health Policy at Duke University.

 
Healthcare Delivery

Much like me, Dr. Yang came to the U.S. from China two decades ago for graduate school. She talked about how she got to know people in U.S. health policy circles and ended up consulting with Congress on financing reform.

She also went into detail about China’s health care opportunity, and its challenges relating to financing (who pays) and delivery (who to care for).

Dr. McClellan noted that health care will again be an important election topic for Democrats, and pointed out that the Duke-Margolis Center for Health Policy is a great place to follow the health care debate during the election cycle.

He still believes market-centered health care delivery plus individual health incentives and responsibility will win the argument.

Healthtech

Dr. McClellan explained that, in his view, the U.S. is not hurting innovation in the healthcare space with its focus on ethical regulations. He also mentioned that “healthtech,” just like fintech, will challenge various parties in both the U.S. and Chinese health care industries in the coming years.

To illustrate his point, he noted that, when China’s NHSA agency was launched, it didn’t even have its own website. 

Health care is a big—and contentious—issue all over the world, and will continue to be debated all over the world, especially during election cycles. Stay tuned as we try to bring more to our future programs on the subject of the health care sector in China. These were both great discussions, and you can listen to the conversation with each guest below.

Versions of this article first appeared on the WisdomTree blog on July 26.

Photo Credit: Azwari Nugraha via Flickr Creative Commons

Disclosure: Certain of the information contained in this article is based upon forward-looking statements, information and opinions, including descriptions of anticipated market changes and expectations of future activity. WisdomTree believes that such statements, information, and opinions are based upon reasonable estimates and assumptions. However, forward-looking statements, information and opinions are inherently uncertain and actual events or results may differ materially from those reflected in the forward-looking statements. Therefore, undue reliance should not be placed on such forward-looking statements, information and opinions.